Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Aptamers industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 Application trends
2.1.5 Technology trends
2.1.6 End-use trends
Chapter 3 Aptamers Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 High advantage of aptamers compared to antibodies
3.2.1.2 Increasing investments in pharmaceutical R&D
3.2.1.3 Rising number of clinical trials to develop aptamer-based therapeutics
3.2.1.4 Increasing prevalence of chronic and rare diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Growing instances of late-stage clinical study setbacks for aptamer therapeutics
3.2.2.2 Low awareness level and incomplete regulatory policies
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By application
3.3.3 By technology
3.3.4 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Aptamers Market, By Type, 2018 - 2032 (USD Million)
5.1 Key trends, by type
5.2 DNA-based aptamers
5.3 RNA-based aptamers
5.4 XNA-based aptamers
Chapter 6 Aptamers Market, By Application, 2018 - 2032 (USD Million)
6.1 Key trends, by application
6.2 Research & development
6.3 Diagnostics
6.4 Therapeutics
6.5 Other applications
Chapter 7 Aptamers Market, By Technology, 2018 - 2032 (USD Million)
7.1 Key trends, by technology
7.2 SELEX
7.3 X-aptamers
7.4 Other technologies
Chapter 8 Aptamers Market, By End-use, 2018 - 2032 (USD Million)
8.1 Key trends, by end-use
8.2 Pharmaceutical & biotechnology companies
8.3 Academic & government research institutes
8.4 CROs
8.5 Other end-users
Chapter 9 Aptamers Market, By Region, 2018 - 2032 (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 SomaLogic
10.2 Aptamer Group
10.3 Aptadel Therapeutics
10.4 Base Pair Biotechnologies
10.5 Vivonics Inc.
10.6 Aptagen, LLC
10.7 TriLink Biotechnologies
10.8 Aptus Biotech
10.9 Novaptech
10.10 NeoVentures Biotechnology Inc.
